EVH earnings call summary

Prepared Highlights

• Q1 2026 total revenue $496M, +9% sequential growth vs Q4 2025 excluding Evolent Care Partners (ECP) (CEO)
• Adjusted EBITDA $22M, in line with expectations (CEO)
• Medical expense ratio (MER) 93%, improving 150 bps vs Q4 2025 excluding ECP (CEO, CFO)
• Performance Suite revenue $323M, +26% sequential vs Q4 2025 excluding ECP, driven by new launches partially offset by exchange membership declines (CFO)
• Specialty Tech & Services revenue $81M, –16% sequential, reflecting exchange membership decline and grace period disenrollment (CFO)
• Administrative services & cases revenue $92M, –11% sequential, due to termination of a client at end of 2025 (CFO)
• Q1 unrestricted cash $142M; net debt $792M; normalized operating cash flow ~–$6M (excluding $15.5M onetime client overpayment and $20M PBM timing) (CFO)
• CapEx $6M in Q1; full-year software/CapEx expected $25M–$30M (CFO)
• New contracts: (1) existing Performance Suite client signed for advanced imaging solution covering 4.5M lives (commercial, Medicaid, Medicare Advantage), go-live Q3; (2) national payer expanding existing oncology + cardiology Performance Suite into new markets, expected annual revenue >$200M, go-live Q3 (CEO)
• Exchange membership decline in Performance Suite — early indicators may be slightly lower than ~40% previously assumed; full-year guidance conservatively assumes 40% decline (CEO, CFO)
• Full-year full-year 2026 cash flow from operations $10M–$20M after ~$60M annual cash interest (CFO)

Official Guidance

Management Quotes

• "Today, Evolent reported strong first quarter results that were in line with our expectations." (CEO)
• "We had a successful launch with Aetna on January 1, supported by strong collaboration with the Aetna team." (CEO)
• "We believe Evolent is recognized as a leader in helping health plans manage both quality and cost for cancer care." (CEO)
• "We continue to expect MER to increase throughout the year and peak in Q3 as we see the full impact of the Highmark launch." (CFO)
• "We believe Q2 will be in line with Q1 due to typical seasonality with a $10 million to $15 million sequential improvement per quarter in both Q3 and Q4." (CFO)

Prepared Metrics

Q&A Batch (1-5 of 10)

Q1 — John Stansel

• Topic: 标准化先审流程对复杂护理（尤其是肿瘤学）的长期影响
• Key points:
  • 公司支持标准化，认为符合AI应用方向，对患者、医生和公司都有利
  • 约95%的审批量来自非肿瘤学（如影像、心脏病），但增长主力在更复杂的肿瘤学（300篇/月期刊新发）
  • AI用于自动化，但不会用于做出不利决定或提出替代方案，需人工介入
• Mgmt stance: bullish（标准化有益，肿瘤学复杂性保障公司不可替代性）

Q2 — Lucas Romanski

• Topic: 一季度MER优于预期原因（肿瘤/心脏病趋势及天气影响）
• Key points:
  • 肿瘤和心脏病基本符合预期，个别市场因会员减少导致患病率略高于预期
  • 该影响已通过合同保护机制预计在后续季度弥补
  • 1月/2月恶劣天气对业务不重大（肿瘤治疗患者会想方设法完成）
• Mgmt stance: neutral（短期波动在可控范围内，合同保护可对冲）

Q3 — Jared Haase

• Topic: Aetna新合作初期指标（临床干预率、医生参与度）
• Key points:
  • 临床

Q&A Batch (6-10 of 10)

Q6 — Mario Ramos

• Topic：医疗趋势异常与合同保护
• Key points：
  • 异常趋势仅集中在少数市场，源于会员下降导致 acuity 显著上升，而非利用率或其他因素。
  • 其他地区趋势稳定，符合预期。
  • 这些市场的 prevalence 风险已在未来合同中获得充分保护。
• Mgmt stance：中性偏乐观——确认趋势可控，且合同提供了保护。

Q7 — Sahil Veeramoney

• Topic：现有 Performance Suite 客户新增先进成像合同（反向交叉销售）
• Key points：
  • 这是首次出现 Performance Suite 客户追加成像服务，属于反向交叉销售先例。
  • 健康计划更倾向于整合少数合作伙伴，而非多个细分供应商。
  • 成像与肿瘤、骨骼、心脏等检查的整合价值凸显，公司计划在此领域持续拓展。
• Mgmt stance：乐观——管理层对此次合作兴奋，并预期将出现更多类似案例。

Q8 — Zachary Haggerty

• Topic：储备与索赔表中的收入真实调减
• Key points：
  • 该季度确认了 $12M 的收入向下真实调减（不利），与索赔端的有利偏差相抵消。
  • 调减源于年底对收入与索赔的估计偏差——当部分市场索赔低于预期时，收入需相应下调。
• Mgmt stance：中性——解释为正常的估计修正过程。

Q9 — David Larsen

• Topic：一季度收入低于预期及全年展望
• Key points：
  • 一季度收入低于共识，但 EBITDA 达标且高于预期；全年收入指引维持不变，隐含约 30% 同比增长。
  • 低点主要因为 Aetna 退出部分市场带来会员下降（符合之前预期），而 Highmark 的会员启动则高于预期。
  • 叠加若干新宣布的大额交易，使季度间收入节奏更难建模，但全年信心反而增强。
• Mgmt stance：乐观——重申指引，且对后续季度更有信心。

Q10 — Eduardo Ron

• Topic：前期索赔有利发展（PYD）构成与影响
• Key points：
  • 该季度净 PYD（扣除收入调整后）略高于 $10M，高于去年同期但全年预计与 2025 年持平。
  • 索赔端 PYD 稍偏重于肿瘤业务，但在具体市场中与之前趋势下降或合同保护的情况一致。
• Mgmt stance：中性——解释 PYD 符合历史模式，且全年预期稳定。